Results 191 to 200 of about 14,856,428 (285)

Clinical features and outcomes of peripheral T-cell lymphoma, not otherwise specified: A single institution retrospective analysis of 30 cases. [PDF]

Oncol Lett
Ma MX, Zhang YL, Xing LN, Wang QY, Qiao S.   +4 more
europepmc   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Can baseline red blood cell distribution width predict outcomes in peripheral T-cell lymphoma patients? [PDF]

Ann Hematol
Lan Y, Zhao Y, Sun J, Zhou, Wang J, Zheng X, Shi Y, Meng H, Wei J, Yang C, Yu W, Jin J, Tong H, Xie W.   +13 more
europepmc   +1 more source

Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity

Rheumatology &Autoimmunity, EarlyView.
Jiekai Tan, Fanlei Hu, Chuanhui Xu
wiley   +1 more source

Neovascular glaucoma at a tertiary Centre in Finland, 2008–2024: A retrospective cohort study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes. Methods Patients with NVG were identified through electronic medical record review.
Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju   +3 more
wiley   +1 more source

Successful Treatment of Peripheral T-cell Lymphoma Not Otherwise Specified in Bilateral Subconjunctiva: A Case Report. [PDF]

Cureus
Ota H, Arihiro K, Mihara K, Chikama TI.
europepmc   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Real-world treatment outcomes of peripheral T-cell lymphoma in the era of molecular targeted therapy. [PDF]

J Clin Exp Hematop
Saburi M, Nishikawa T, Maehara K, Takata H, Sakata M, Sasaki H, Abe M, Kohno K, Kusaba T, Urabe S, Kondo Y, Nakayama T, Ohtsuka E.   +12 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. [PDF]

Ann Hematol
Ballerini M, Lucchini E, Ravano E, Rosa J, Patti C, Arcari A, Cavallo F, Ballotta L, Loseto G, Evangelista A, Tabanelli V, Zaja F.   +11 more
europepmc   +1 more source